Patent Issued for Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor (USPTO 11679082).
In: Immunotherapy Weekly, 2023-07-11, S. 1758-1758
serialPeriodical
Zugriff:
A therapeutic construct comprising: a mesoporous silica nanoparticle (MSNP) comprising platform loaded with: a small molecule mitotic kinase inhibitor in an amount 0.01% to 5% by weight of the therapeutic construct, or a mitotic kinase-specific siRNA; and a Programmed Death-Ligand 1 (PD-L1) antibody conjugated onto the MSNP platform. The method of claim 17, further comprising administering to the subject an anti-cancer therapy comprising an anti-cancer agent or any form of radiation therapy." Keywords: Antibodies; Blood Proteins; Cancer; Clinical Research; Clinical Trials and Studies; Drugs and Therapies; Emerging Technologies; Enzymes and Coenzymes; Genetics; Health and Medicine; Hematology; Immunoglobulins; Immunology; Kinase; Leukemia; Nanoparticles; Nanotechnology; Oncology; Oregon Health & Science University; Proteins; Therapeutics; Therapy EN Antibodies Blood Proteins Cancer Clinical Research Clinical Trials and Studies Drugs and Therapies Emerging Technologies Enzymes and Coenzymes Genetics Health and Medicine Hematology Immunoglobulins Immunology Kinase Leukemia Nanoparticles Nanotechnology Oncology Oregon Health & Science University Proteins Therapeutics Therapy 1758 1758 1 07/10/23 20230711 NES 230711 2023 JUL 11 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Oregon Health & Science University (Portland, Oregon, United States) has been issued patent number 11679082, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Patent Issued for Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor (USPTO 11679082).
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2023-07-11, S. 1758-1758 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Schlagwort: |
|
Sonstiges: |
|